The Skin Cancer Drugs Market: 2018 – 2030 – Opportunities, Challenges, Strategies & Forecasts

Release Date: January 2018
Number of Pages: 230
Number of Tables and Figures: 45
​
Skin cancer, the uncontrolled growth of abnormal skin cells, is among the most common types of cancer. With the exception of melanoma, most skin cancers are not life threatening. However, early diagnosis and treatment are critical to avoid functional or cosmetic deformities that can result from the invasion and damage of nearby tissues and organs.

Although surgery is the most common treatment for skin cancer, drugs – including chemotherapy, immunotherapy and targeted agents – are widely used for treating advanced forms of skin cancer. Drug developers are investing heavily in new drug development programs for skin cancer, primarily in the areas of melanoma, BCC (Basal Cell Carcinoma) and SCC (Squamous Cell Carcinoma). 

As new drugs continue to revitalize skin cancer treatment options, we expect the skin cancer drugs market to grow at a CAGR of approximately 10% between 2018 and 2021, eventually accounting for more than $4.7 Billion in revenue. 
The “Skin Cancer Drugs Market: 2018 – 2030 – Opportunities, Challenges, Strategies & Forecasts” report presents an in-depth assessment of the skin cancer drugs ecosystem including therapeutic areas, treatment options, key trends, market drivers, challenges, investment potential, leading therapies, drug development pipeline, opportunities, future roadmap, value chain, ecosystem player profiles and strategies. The report also presents market size forecasts for skin cancer drugs from 2018 through to 2030. The forecasts are segmented for 3 drug classes, 4 therapeutic categories, 5 regions and 25 leading countries. 

The report comes with an associated Excel datasheet suite covering quantitative data from all numeric forecasts presented in the report.
For a Sample and Table of Contents please contact info@snsintel.com

Pricing: The report is available for the following price:

Single User License: USD 2,500

Company Wide License (Single Site): USD 3,500

Company Wide License (Global Site): USD 6,500

Key Findings:
The report has the following key findings:
  • Drug developers are investing heavily in new drug development programs for skin cancer, primarily in the areas of melanoma, BCC and SCC. These three indications collectively constitute more than 80% of all drug development programs for skin cancers.
  • As new drugs continue to revitalize skin cancer treatment options, we expect the skin cancer drugs market to grow at a CAGR of approximately 10% between 2018 and 2021, eventually accounting for more than $4.7 Billion in revenue.
  • Immunotherapies – primarily monoclonal antibodies – are continuing to gain a strong foothold in the skin cancer drugs market with a number of recent approvals such as anti-PD-L1 antibody Avelumab (Bavencio) for the treatment of MCC (Merkel Cell Carcinoma), and anti-PD-1 antibody Nivolumab (Opdivo) for completely resected melanoma.
  • A major focus of late-stage drug development programs is on monoclonal antibodies, IDO1 inhibitors, BRAF and MEF inhibitors, TKIs (Tyrosine Kinase Inhibitors), and oncolytic viruses and vaccines.

Topics Covered:
The report covers the following topics:
  • Skin cancer drugs ecosystem
  • Market drivers and barriers
  • Review of melanoma and non-melanoma skin cancers 
  • Role of drugs in skin cancer and key trends
  • Analysis of key drug classes and leading skin cancer drugs
  • Future drug development pipeline
  • Industry roadmap and value chain
  • Profiles and strategies of over 80 leading ecosystem players, including skin cancer drug developers
  • Strategic recommendations for ecosystem players
  • Market analysis and forecasts from 2018 till 2030

Forecast Segmentation:
Market forecasts are provided for each of the following submarkets and their subcategories:
  • Drug Class
    • Chemotherapy
    • Immunotherapy
    • Targeted Agents & Other Drugs
  • Therapeutic Category
    • Melanoma
    • BCC/SCC (Basal and Squamous Cell Carcinoma)
    • MCC (Merkel Cell Carcinoma)
    • Other Skin Cancers
  • Regional Markets
    • Asia Pacific
    • Europe
    • Latin & Central America
    • Middle East & Africa
    • North America
  • Countries 
    • Brazil
    • Canada
    • China
    • Egypt
    • France
    • Germany
    • Greece
    • India
    • Israel
    • Italy
    • Japan
    • Mexico
    • Netherlands
    • Poland
    • Portugal
    • Russia
    • Saudi Arabia
    • South Korea
    • Spain
    • Switzerland
    • Taiwan
    • Turkey
    • UK
    • USA

Key Questions Answered:
The report provides answers to the following key questions:
  • How big is the skin cancer drugs opportunity?
  • What trends, challenges and barriers are influencing its growth?
  • How is the ecosystem evolving by segment and region?
  • What will the market size be in 2020 and at what rate will it grow?
  • Which countries and submarkets will see the highest percentage of growth?
  • What are the prospects of immunotherapy drugs in skin cancer treatment?
  • How big is the market for melanoma drugs?
  • Who are the key market players and what are their strategies?
  • How will patent expirations of innovator drugs impact the market?
  • What strategies should skin cancer drug developers adopt to remain competitive?


List of Companies Mentioned:
The following companies and organizations have been reviewed, discussed or mentioned in the report:

AB Science
AbbVie
Adaptimmune Therapeutics
Agenus
Almirall
Altor Bioscience
Amgen
Angimmune
Antigen Express (Generex Biotechnology Corporation)
APCure
Array BioPharma
Ascend Biopharmaceuticals
Astex Pharmaceuticals
AstraZeneca
Basilea Pharmaceutica
Berg
BioLineRx
Biosceptre
BMS (Bristol-Myers Squibb)
Boehringer Ingelheim
Boston Biomedical
Caladrius Biosciences
Celgene Corporation
Celldex Therapeutics
CEL-SCI Corporation
Cipla
CK Life Sciences
Cytori Therapeutics
Daiichi Sankyo
Dr. Reddy’s Laboratories
Eisai
Eleven Biotherapeutics
Eli Lilly and Company
Elios Therapeutics
Exelixis
Fresenius Kabi
Galderma
Galectin Therapeutics
Glycotope
GSK (GlaxoSmithKline)
HedgePath Pharmaceuticals
Hikma Pharmaceuticals
Idera Pharmaceuticals
Immune Design
Immunocore
Incyte Corporation
Innate Pharma
Inovio Pharmaceutical
Institut Mérieux
Iovance Biotherapeutics
IRX Therapeutics
Johnson & Johnson
Karyopharm Therapeutics
Leap Therapeutics
LEO Pharma
Lupin
MacroGenics
Mayne Pharma Group
Meda Pharmaceuticals
Merck & Co.
Merck KGaA
Millennium Pharmaceuticals
Molecular Templates
Morphotek
Mylan
NantKwest
Nestlé Health Science
Nestlé Skin Health
NewLink Genetics
Novartis
Oncolytics Biotech
OncoSec Medical
Ono Pharmaceutical Company
Orbis Health Solutions
Otsuka Holdings Company
Otsuka Pharmaceutical Company
Perseus Holdings USA
Pfizer
Philogen
Pierre Fabre (Laboratoires Pierre Fabre)
Plexxikon
Polaris Pharmaceuticals
Polynoma
Prometheus Laboratories
Provectus Biopharmaceuticals
Reata Pharmaceuticals
Regeneron Pharmaceuticals
Roche Holding (F. Hoffmann-La Roche)
RXi Pharmaceuticals Corporation
Sanofi
Sanofi Genzyme
Seattle Genetics
Sumitomo Dainippon Pharma
Sun Pharma (Sun Pharmaceutical Industries)
Syndax Pharmaceuticals
Taiho Pharmaceutical Company
Takara Bio
Takeda Pharmaceutical Company
Teva Pharmaceutical Industries
Transgene
U.S. FDA (Food and Drug Administration)
Valeant Pharmaceuticals
Vidac Pharma
Viralytics